PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced more than $500,000 in new grants to more than a dozen educational institutions and organizations working to enhance the teaching and learning of ...

The executive at Bristol Myers Squibb Co. (NYSE:BMY) has admitted to using his inside knowledge of Bristol Myers Squibb Co. (NYSE:BMY)'s potential takeover targets to buy options in the companies, including Amylin Pharmaceuticals, prior to the ...

BIO-TECH STOCKS: AcelRx Pharmaceuticals Inc, Bristol Myers Squibb Co., ImmunoCellular Therapeutics Ltd, Infinity Pharmaceuticals Inc. Forward · Print · Save · Repost This.

... SC In China. BMS, Simcere Pharma To Co-Develop Orencia� SC In China. Tech & Pharma June 17, 2013. BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia� for the treatment of rheumatoid arthritis in China.

Recent news about Bristol Myers Squibb Co. (NYSE:BMY)'s latest oncology drug candidate might be such a case. The company recently announced encouraging Phase I testing data on the drug nivolumab, which helps the immune system attack cancerous ...

Investors considering a purchase of Bristol-Myers Squibb Bristol-Myers Squibb Co. (NYSE: BMY) stock, but tentative about paying the going market price of $47.16/share, might benefit from considering selling puts among the alternative strategies at ...

TRENTON, N.J. - Federal prosecutors in New Jersey say a former executive for biopharmaceuticals company Bristol-Myers Squibb has admitted using his high-level position and access to nonpublic information to make about $310,000 from insider trades.

Sorry - as some commenters noted on my last post (which was a billionty years ago), I've gone a bit quiet. No real excuse except I've been busy helping set up and settle an Afghan interpreter and his wife into life here in Palmy.

PRINCETON, N.J. & NANJING, China--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and Simcere Pharmaceutical Group (NYS: SCR) , a leading pharmaceutical company in China, today announced that the companies have expanded ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Na�ve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of ...